Exhibit 10.3

***Text Omitted and Filed Separately with the Securities and Exchange
Commission.

Confidential Treatment Requested Under

17 C.F.R. Sections 200.80(b)(4) and 240.24b-2

AMENDMENT TO

MANUFACTURING AND SUPPLY AGREEMENT

This Amendment (the “Amendment”) is effective as of September 25, 2013
(“Amendment Effective Date”) by and between sanofi-aventis U.S. LLC, with
offices at 55 Corporate Drive, Bridgewater, NJ 08807 (“Sanofi”), and Horizon
Pharma USA, Inc., with offices at 520 Lake Cook Road, Suite 520, Deerfield, IL
60015 (hereinafter “Horizon”, and together with Sanofi, the “Parties”).

WHEREAS , the Parties entered into a Manufacturing and Supply Agreement (as
amended, the “Agreement”), effective as of May 25, 2011 (the “Effective Date”);
and

WHEREAS, as of the date hereof Sanofi and Horizon wish to amend the terms of the
Agreement as set forth below.

NOW, THEREFORE, in consideration of mutual covenants the Parties agree as
follows:

 

1.

Article 6. FORECASTS AND ORDERS: Section 6.1 (Organization of the Production
Site); Section 6.2 (Communication of Forecasts and Purchase Orders by Horizon);
and Section 6.3(b) (Confirmation by sanofi-aventis). Article 6 is hereby
modified by making the “Organizational Change” rights, duties, and obligations
of both parties set out therein, only applicable and effective starting
[...***...].

 

2.

2014 Purchase Orders.

 

a.

3x3 Count. Upon the full execution of this Amendment, Horizon shall issue a
Purchase Order for the calendar year 2014, for [...***...] 3x3 ct blisters of
Product.

 

b.

90 Count. Upon the full execution of this Amendment, Horizon shall issue a
Purchase Order for the calendar year 2014, for [...***...] 90 ct bottles of
Product.

 

3.

Exhibit 1. Exhibit 1 to the Agreement is hereby replaced in its entirety with
the attached Exhibit 1.

IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by
their duly authorized representatives as of the date first above written.

   

 

sanofi-aventis US LLC

   

   

   

Horizon Pharma USA, Inc.

   

   

   

   

   

By

   

/s/ Kenneth J. Bruss

   

   

   

By

   

/s/ Jeffrey W. Sherman, MD

Name

   

Kenneth J. Bruss

   

   

   

Name

   

Jeffrey W. Sherman, MD

Title

   

KCIA Site Head

   

   

   

Title

   

Chief Medical Officer

Date

   

10/7/2013

   

   

   

Date

   

24 Sep 2013

   

   

   

                       

 

***Confidential Treatment Requested

--------------------------------------------------------------------------------

   

Exhibit 1 Amended

DUEXIS Pricing

Table 1 – 2013 selling prices

   

 

Configuration

      

Base Selling

Price

      

API Cost & API
Freight

      

Total Selling
Price

      

Base Selling
Price

      

API Cost & API
Freight

      

Total Selling
Price

   

      

   

      

< [...***...]

      

   

      

> [...***...]

90ct Bottle

      

As Per
table 1.1

      

As Per
table 1.1

      

As Per
table 1.1

      

[...***...]

   

[...***...]

   

[...***...]

*15x1ct blister

      

[...***...]

      

[...***...]

      

[...***...]

      

[...***...]

      

[...***...]

      

[...***...]

*3x3ct blister

      

[...***...]

      

[...***...]

      

[...***...]

      

[...***...]

      

[...***...]

      

[...***...]

Latin America Bulk -per 1000 tablets

      

[...***...]

      

[...***...]

      

[...***...]

      

N/A

      

N/A

      

N/A

 

*

Price based on blister material as non-child proof Aclar,

 

1.

Such pricing is subject to adjustment pursuant to Articles 5 and 9 of the
Agreement.

 

2.

Such pricing is based on and applies to annual production for the given Contract
Year.

 

3.

Such pricing includes packaging in a round 90ct bottle or single one count
(1ct) blister packaged in a (15 x 1ct) per specifications in Exhibit 2. Pricing
for other SKUs, such samples and blister packaging shall be agreed in writing by
the Parties.

 

4.

Such pricing is exclusive of all taxes

Table 1.1 – DUEXIS 90count Bottle Pricing Schedule for volumes < [...***...]

   

 

Calendar Year

      

2013

   

2014

   

2015

   

2016

   

2017

   

2018

Base Bottle Price

      

[...***...]

   

[...***...]

   

[...***...]

   

[...***...]

   

[...***...]

   

[...***...]

API Price per 90 count ( 2013)

      

[...***...]

   

[...***...]

   

[...***...]

   

[...***...]

   

[...***...]

   

[...***...]

*90ct selling price

      

[...***...]

   

[...***...]

   

[...***...]

   

[...***...]

   

[...***...]

   

[...***...]

90ct purchase volume

      

[...***...]

   

[...***...]

   

[...***...]

   

[...***...]

   

[...***...]

   

[...***...]

 

*

API price shall be adjusted [...***...] beginning in [...***...] as per section
9.3(b) of the Agreement.

 

***Confidential Treatment Requested

--------------------------------------------------------------------------------